Extended Data Fig. 2. Refining epitope labelling of fibrillin recombinant fragment.

Mab2502 (clone 26 (epitope within residues 45–450 from epitope mapping¹³)) and Mab1919 (clone 11C1.3 (epitope within residues 451–909 as defined by manufacturer)) were used to probe overlapping recombinant fibrillin fragments to more accurately define their epitopes in fibrillin-1. (Ai and Bi) schematic diagrams of recombinant fragments N-Ter, PF1, PF2, PF3, PF4, PF5, Ex3-11 and Ex4-11. Recombinant fibrillin-1 fragments after separation by SDS-PAGE in the presence (R) or absence (NR) of a reducing agent followed by western blotting with either (Aii) Mab2502 or (Bii) Mab1919. These blots were repeated at least 3 times. The antibody epitopes for mab2502 (45–450¹³) and mab1919 (451–909) are narrowed down to TB1-PRR (residues 330–450) and cbEGF7-Hyb2 (residues 723-909) respectively, highlighted in red. (C) Number of peptides identified by LC-MS/MS from each domain of fibrillin, where a protease resistant region is located between TB1 to TB2 (TB domains are numbered) and indicated by an asterisk (redrawn from⁴¹). (D) Diagram of the fibrillin microfibril repeating unit with the binding sites of Mab2502 and Mab1919 in adult human ciliary zonule microfibrils (as determined in³⁸) and putative location of the protease resistant region identified in⁴¹. Panel c adapted from ref. ⁴¹ under a Creative Commons licence CC BY 4.0.